Herbal Monograph
Barberry
Berberis vulgaris L.
Berberidaceae
Potent bitter tonic and liver herb rich in berberine for digestive, metabolic, and antimicrobial support
Overview
Plant Description
Berberis vulgaris is a deciduous, thorny shrub growing 1-3 meters (3-10 feet) tall, with arching, grooved branches bearing clusters of sharp three-pronged spines (modified leaves) at the nodes, typically 1-2 cm long. The bark of young stems is yellowish-grey; the inner bark and wood are intensely bright yellow due to high berberine content -- a characteristic diagnostic feature of the genus. Leaves are small, obovate to spatulate, 2-5 cm long, arranged in fascicles from short lateral shoots, with finely serrate margins bearing small, bristle-tipped teeth. The leaves emerge bright green in spring and may turn reddish in autumn. Flowers are small (6-8 mm diameter), bright yellow, six-petaled, arranged in pendulous racemes of 10-30 flowers, blooming from April to June. They are mildly fragrant and pollinated by insects. The stamens are touch-sensitive (thigmonastic) -- when touched at the base they spring inward rapidly, a remarkable adaptation for ensuring pollen transfer to visiting insects. The fruit is an oblong, bright red to dark crimson berry, 8-12 mm long, ripening in late summer to autumn, borne in drooping clusters. The berries are edible but very tart (high in vitamin C and malic acid), traditionally used for preserves, syrups, and acidulant in Middle Eastern cuisine. The root system is extensive, with thick, woody, bright yellow roots.
Habitat
Berberis vulgaris is a hardy, adaptable shrub that thrives in a wide range of habitats. It grows naturally in hedgerows, woodland margins, scrubland, rocky hillsides, and limestone outcrops. It prefers well-drained, calcareous (chalky or limestone) soils but tolerates a broad range of soil types including clay and sandy soils. It is drought-tolerant once established and thrives in full sun to partial shade. In its native range it is found from lowlands to montane zones up to approximately 2000 meters elevation. In North America, where it was introduced by early European colonists for hedging and dye production, it has become naturalized and is considered invasive in some northeastern states. It was widely eradicated in the early 20th century in North American wheat-growing regions because it serves as an alternate host for wheat stem rust fungus (Puccinia graminis).
Distribution
Native to central and southern Europe, northwest Africa, and western Asia (Iran, Turkey, Caucasus region). Its natural range extends from the British Isles and Scandinavia (southern) through central Europe to the Mediterranean basin and eastward through Asia Minor to the Caucasus, Iran, and Central Asia. Widely naturalized in North America (northeastern United States and southeastern Canada), where it was introduced in the 17th century by European settlers. Also introduced and occasionally naturalized in parts of South America, Australia, and New Zealand. In its native European range, populations have declined in some regions due to wheat rust eradication programs and land-use changes. Iran remains a major center of traditional use and ongoing pharmacological research.
Parts Used
Root bark (Cortex Berberidis radicis)
Preferred: Dried root bark for decoction or tincture; powdered root bark in capsules
The primary medicinal part of B. vulgaris. The root bark contains the highest concentration of berberine (2-6%) and other isoquinoline alkaloids. It is the part specified in the British Herbal Pharmacopoeia, the Eclectic Materia Medica, and most Western herbal traditions. The intensely bitter taste and bright yellow color are indicators of alkaloid content. Root bark is preferred over whole root because alkaloid concentration is highest in the bark layer, with the inner woody core contributing less medicinal value per unit weight.
Stem bark (Cortex Berberidis)
Preferred: Dried stem bark for decoction or tincture
The stem bark contains berberine and related alkaloids at somewhat lower concentrations than root bark (typically 1.5-3%). It is more readily harvested from prunings without sacrificing the whole plant. Used interchangeably with root bark in some traditions, particularly in European folk medicine. The British Herbal Pharmacopoeia (1983) lists stem bark as an acceptable alternative to root bark.
Fruit (Fructus Berberidis, barberries)
Preferred: Fresh or dried whole berries; barberry fruit syrup or juice
The ripe berries are the mildest medicinal part, containing very low levels of berberine (trace amounts in the pulp) but rich in organic acids (malic acid, citric acid), vitamin C (ascorbic acid, approximately 30-50 mg per 100 g fresh weight), pectin, and anthocyanins (in the skin). Used as food, condiment, and mild medicine. In Iranian cuisine, dried barberries (zereshk) are a prized ingredient in rice dishes and stews. Medicinally, the fruit is used as a cooling refrigerant, mild laxative, and source of vitamin C. The seeds within the berries contain higher alkaloid levels than the fruit pulp.
Whole root (Radix Berberidis)
Preferred: Dried whole root, powdered or chopped for decoction
The whole root, including both bark and woody core, is sometimes used when powdered for capsules or in traditional decoctions. Alkaloid content is lower per gram than isolated root bark due to dilution by the less alkaloid-rich inner wood. Some traditional preparations and commercial products use whole root rather than isolated root bark.
Key Constituents
Isoquinoline alkaloids (protoberberine type)
The isoquinoline alkaloids, dominated by berberine, are the primary pharmacologically active constituents of barberry. They are collectively responsible for the antimicrobial, cholagogue, hepatoprotective, bitter tonic, anti-inflammatory, hypoglycemic, and hypolipidemic activities attributed to the plant. The total alkaloid content of root bark (typically 3-8% combined alkaloids) determines its medicinal potency, and the bright yellow color intensity serves as a rough indicator of alkaloid content. The presence of multiple structurally related alkaloids creates a broader spectrum of activity than berberine alone, and some alkaloids (berbamine, oxyacanthine) contribute unique cardiovascular and immunomodulatory effects not attributable to berberine. Whole plant extracts may have a different therapeutic profile than isolated berberine due to these synergistic and complementary alkaloid interactions.
Tannins and polyphenols
Tannins contribute astringent, antidiarrheal, and tissue-toning properties that complement the antimicrobial action of the alkaloids, particularly in GI tract applications. The combination of berberine's antimicrobial action with tannin astringency makes barberry a well-rounded remedy for infectious diarrhea and dysentery in traditional use.
Organic acids and vitamins (fruit)
The organic acids and vitamin C content of barberry fruit underpin its traditional use as a refrigerant, cooling tonic, and nutritive agent. The fruit has a distinct therapeutic profile from the bark, being much milder and lacking significant alkaloid content. In Iranian traditional medicine, barberry fruit (zereshk) is valued as a food-medicine for its cooling, thirst-quenching, and liver-supporting properties.
Other constituents
Minor constituents that contribute to the overall character of whole-plant preparations but are not considered primary drivers of therapeutic activity.
Herbal Actions
Kills or inhibits the growth of microorganisms
One of the most well-documented actions of barberry, driven primarily by berberine and the total alkaloid fraction. Berberine demonstrates broad-spectrum in vitro antimicrobial activity against Gram-positive bacteria (Staphylococcus aureus, Streptococcus spp., including MRSA in some studies), Gram-negative bacteria (Escherichia coli, Salmonella spp., Vibrio cholerae, Shigella spp.), fungi (Candida albicans, dermatophytes), and protozoa (Giardia lamblia, Entamoeba histolytica, Leishmania spp., Trichomonas vaginalis). Mechanisms include inhibition of bacterial FtsZ protein (cell division), DNA intercalation, efflux pump inhibition (berberine inhibits NorA efflux pump in S. aureus, potentially reversing antibiotic resistance), disruption of cell membrane integrity, and inhibition of biofilm formation. Clinical evidence for antimicrobial application is primarily traditional and in vitro, with limited whole-plant clinical trials but extensive purified berberine data supporting anti-infective effects, particularly against GI pathogens.
[3, 4, 11, 12]Stimulates bile flow from the gallbladder
Barberry is one of the preeminent cholagogue (bile-stimulating) herbs in Western herbal tradition. Berberine stimulates bile secretion (choleresis) through direct action on hepatocytes and biliary epithelial cells. Animal studies demonstrate increased bile volume and bilirubin excretion following berberine administration. The bitter taste activates bitter taste receptors (T2Rs) on the tongue and throughout the GI tract, reflexively stimulating bile flow, gastric acid secretion, and pancreatic enzyme release. The British Herbal Pharmacopoeia specifically lists barberry as a cholagogue indicated for gallbladder dysfunction and cholecystitis. This action makes barberry particularly valuable in formulas for sluggish digestion, biliary congestion, and functional liver-gallbladder complaints.
[1, 2, 5, 11]Protects the liver from damage
Berberine and barberry extracts demonstrate significant hepatoprotective activity in multiple experimental models of liver injury. Mechanisms include: antioxidant protection of hepatocytes (scavenging reactive oxygen species, enhancing glutathione, SOD, and catalase), inhibition of hepatic NF-kB-mediated inflammatory pathways, reduction of hepatic lipid accumulation (anti-steatotic effect through AMPK activation), stimulation of bile flow (facilitating toxin clearance), and inhibition of hepatic stellate cell activation (anti-fibrotic). Clinical studies with berberine have demonstrated reduction in liver enzymes (ALT, AST) in patients with non-alcoholic fatty liver disease (NAFLD). The combined cholagogue and hepatoprotective actions make barberry one of the most important liver herbs in the Western herbal tradition.
[1, 10, 11, 12]Stimulates digestive secretions via bitter taste receptors
Barberry is classified as a strong bitter herb (amarum) in Western herbal pharmacology. The intensely bitter taste is due primarily to the isoquinoline alkaloids, especially berberine and palmatine. Bitter compounds activate T2R bitter taste receptors on the tongue, triggering the cephalic phase of digestion: increased salivation, gastric acid secretion, pepsinogen release, bile flow, and pancreatic enzyme output. This bitter reflex pathway is the basis for barberry's traditional use as a digestive stimulant and appetite restorative. The British Herbal Pharmacopoeia classifies barberry among the bitter tonics. In clinical herbalism, barberry's bitter action is considered specific for conditions of digestive torpor with hepatobiliary congestion -- the classic 'sluggish liver' presentation.
[1, 2, 5]Reduces inflammation
Berberine is a well-documented anti-inflammatory agent acting through multiple pathways: inhibition of NF-kB signaling (preventing nuclear translocation and target gene transcription), suppression of pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6), inhibition of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS), and activation of AMPK (which has anti-inflammatory downstream effects). In vivo studies demonstrate suppression of carrageenan-induced paw edema, colitis models, and various inflammatory conditions. The anti-inflammatory action supports the use of barberry in conditions involving hepatic inflammation, GI mucosal inflammation, and inflammatory skin conditions.
[10, 11, 12]Gradually restores proper body function and increases overall health
In the Eclectic and traditional Western herbal classification, barberry is considered an alterative -- an agent that gradually restores proper body function, particularly through improving hepatobiliary and digestive function and supporting eliminative pathways. The combination of cholagogue, hepatoprotective, mild laxative, and antimicrobial actions collectively promote detoxification, improve nutrient assimilation, and clear metabolic waste. Eclectic physicians specifically recommended barberry as a blood purifier for chronic skin conditions, arthritis, and general debility attributed to hepatic insufficiency.
[1, 5]Tightens and tones tissue, reduces secretions
The tannin content of barberry bark contributes an astringent action that tightens and tones mucosal tissues. This astringency complements the antimicrobial alkaloids in treating diarrhea, dysentery, and GI mucosal inflammation. The astringent quality also applies to topical applications for wound healing and oral mucosal conditions.
[1, 2]Promotes bowel movement
Barberry bark, particularly in larger doses, can have a mild laxative effect attributed to its stimulation of bile flow (bile acts as a natural laxative in the GI tract) and direct effects of berberine on intestinal smooth muscle tone and secretion. The laxative effect is dose-dependent: smaller doses are primarily bitter-tonic and astringent, while larger doses become more laxative through cholagogue and prokinetic mechanisms. This mild laxative action supports its use in conditions of hepatic and intestinal stagnation.
[1, 5]Increases urine production and output
A mild diuretic effect has been attributed to barberry in traditional European and Unani medicine. The mechanism is not well characterized but may relate to berberine's effects on renal hemodynamics and tubular transport. The traditional indication for urinary tract support is documented in multiple historical sources, though modern clinical evidence for the diuretic action specifically is limited.
[5, 6]Prevents or slows oxidative damage to cells
Barberry extracts demonstrate significant antioxidant activity in both bark and fruit preparations. Zovko Koncic et al. (2010) documented strong radical-scavenging activity (DPPH, superoxide) in B. vulgaris bark extracts, attributed to both alkaloid and polyphenolic fractions. Berberine itself demonstrates antioxidant effects through scavenging of reactive oxygen species, enhancement of endogenous antioxidant enzymes (SOD, catalase, glutathione peroxidase), and inhibition of lipid peroxidation. The fruit contributes additional antioxidant capacity through anthocyanins and vitamin C. The antioxidant action is considered secondary as it supports rather than defines the primary therapeutic applications.
[10, 11]Therapeutic Indications
Hepatobiliary System
Gallbladder dysfunction and biliary congestion
One of the primary traditional and pharmacologically validated indications for barberry. The cholagogue action (stimulation of bile flow) is well-documented in animal studies and supported by extensive clinical tradition. The British Herbal Pharmacopoeia (1983) specifically indicates barberry for cholecystitis and gallbladder dysfunction. Berberine increases bile volume, bile salt secretion, and bilirubin excretion in experimental models. The combined bitter tonic and cholagogue actions make barberry particularly effective for functional biliary complaints presenting with upper abdominal discomfort, fat intolerance, bloating, and pale stools indicative of insufficient bile flow. Often combined with Cynara scolymus (artichoke) or Taraxacum officinale (dandelion root) in cholagogue formulas.
[1, 2, 11]Non-alcoholic fatty liver disease (NAFLD) and hepatic steatosis
Multiple RCTs using purified berberine (900-1500 mg/day) have demonstrated significant improvements in hepatic fat content, liver enzymes (ALT, AST), and metabolic parameters in NAFLD patients. Berberine activates hepatic AMPK, which inhibits lipogenesis and promotes fatty acid oxidation, directly addressing the pathophysiology of hepatic steatosis. Yan et al. (2015) RCT demonstrated significant reduction in hepatic fat content measured by proton magnetic resonance spectroscopy. While these trials used purified berberine rather than whole barberry, the hepatoprotective and cholagogue actions of whole barberry extracts provide a strong rationale for clinical use, particularly in combination with dietary and lifestyle interventions.
[7, 11, 12]Jaundice and hepatic insufficiency (traditional)
Barberry has been used for centuries across multiple medical traditions for jaundice -- one of its common names is 'Jaundice Berry.' In Eclectic medicine, barberry was specifically indicated for jaundice arising from biliary obstruction or hepatic torpor. The yellow color of the bark was seen as a 'signature' for liver and bile diseases in the Doctrine of Signatures. The cholagogue and hepatoprotective actions provide pharmacological support for this traditional indication. However, jaundice requires proper medical evaluation to determine the underlying cause, and barberry should only be used as supportive therapy under qualified guidance.
[1, 5, 6]Digestive System
Infectious diarrhea and dysentery
One of the best-established indications for berberine-containing plants. Multiple clinical trials (primarily with purified berberine) have demonstrated efficacy against bacterial and protozoal diarrhea. Rabbani et al. (1987) landmark RCT showed berberine significantly reduced diarrhea volume and duration in cholera patients. Berberine inhibits intestinal secretory responses to bacterial enterotoxins (cholera toxin, E. coli heat-stable and heat-labile toxins) while simultaneously exerting direct antimicrobial effects against enteropathogens. The combined antimicrobial + antisecretory + astringent (tannin) actions of whole barberry preparations make it a well-rounded antidiarrheal agent. This is the best-documented clinical application of berberine and berberine-containing plants historically.
[4, 9, 11]Digestive insufficiency and poor appetite (dyspepsia)
The bitter tonic action of barberry reflexively stimulates the entire digestive cascade: salivation, gastric acid secretion, pepsinogen release, bile flow, and pancreatic enzyme output. This makes it indicated for functional dyspepsia characterized by poor appetite, sluggish digestion, postprandial bloating, and a sensation of heaviness after meals. Particularly indicated when dyspepsia is accompanied by signs of hepatobiliary insufficiency (pale stools, fat intolerance, coated tongue). The British Herbal Pharmacopoeia lists barberry among bitter tonics for dyspeptic conditions.
[1, 2, 5]Intestinal infections (Giardia, Candida, bacterial overgrowth)
Berberine has demonstrated in vitro and clinical activity against intestinal pathogens including Giardia lamblia, Entamoeba histolytica, and Candida species. Clinical trials in giardiasis have shown berberine to be effective, though somewhat less potent than metronidazole in direct comparisons. The broad-spectrum antimicrobial activity against multiple GI pathogens, combined with the secretory inhibiting and astringent effects, makes barberry valuable for intestinal infections, particularly in a clinical herbalism context where multi-targeted approaches are preferred.
[11, 12]Endocrine System
Type 2 diabetes mellitus (blood glucose regulation)
The hypoglycemic effect of berberine is one of the most robustly documented actions, supported by multiple meta-analyses. Dong et al. (2012) meta-analysis of 14 RCTs (n=1068) found berberine significantly reduced fasting blood glucose (WMD -0.90 mmol/L), HbA1c (WMD -0.72%), fasting insulin, and HOMA-IR compared to placebo or lifestyle intervention, with efficacy comparable to metformin in head-to-head trials. The primary mechanism is AMPK activation, which enhances glucose uptake via GLUT4 translocation, inhibits hepatic gluconeogenesis, improves insulin receptor expression and insulin sensitivity, and modulates gut microbiome composition (increasing short-chain fatty acid-producing bacteria). IMPORTANT CAVEAT: Most RCTs used purified berberine hydrochloride (typically 500 mg three times daily), not whole barberry extracts. While the mechanism is directly relevant to barberry's berberine content, dosage equivalence between purified berberine and whole herb preparations requires consideration.
[7, 11, 12]Metabolic syndrome and insulin resistance
Berberine addresses multiple components of metabolic syndrome simultaneously: hyperglycemia (AMPK activation), dyslipidemia (LDL receptor upregulation), hepatic steatosis (reduced lipogenesis), visceral adiposity (enhanced fat oxidation), and systemic inflammation (NF-kB inhibition). Clinical studies have demonstrated improvements in multiple metabolic parameters concurrently. A whole barberry approach adds the cholagogue and bitter tonic actions that further support metabolic health through improved digestive function and bile acid metabolism.
[7, 8, 11]Polycystic ovary syndrome (PCOS) with insulin resistance
Several clinical trials have investigated berberine for PCOS, showing improvements in insulin resistance, androgen levels, and ovulatory function. An et al. (2014) found berberine comparable to metformin in improving insulin sensitivity and reducing androgen levels in PCOS patients. This application derives from berberine's metabolic effects (AMPK activation, improved insulin signaling) rather than direct hormonal action. Preliminary but promising clinical evidence.
[7, 11]Cardiovascular System
Hyperlipidemia (elevated LDL cholesterol and triglycerides)
The hypolipidemic effect of berberine is supported by multiple meta-analyses. Lan et al. (2015) meta-analysis of 27 RCTs (n=2569) demonstrated that berberine significantly reduced total cholesterol (WMD -0.61 mmol/L), LDL-C (WMD -0.65 mmol/L), and triglycerides (WMD -0.50 mmol/L) while modestly increasing HDL-C. The primary mechanism is upregulation of hepatic LDL receptor expression through a unique post-transcriptional mRNA-stabilizing mechanism (distinct from statin action on HMG-CoA reductase), increasing LDL clearance from the blood. Berberine also inhibits PCSK9, further enhancing LDL receptor availability. Additional mechanisms include AMPK-mediated inhibition of lipogenesis and enhanced fatty acid oxidation. IMPORTANT CAVEAT: As with glucose-lowering data, most trials used purified berberine, not whole barberry.
[7, 8, 11]Hypertension (mild, adjunctive)
Berberine and related barberry alkaloids (berbamine, oxyacanthine) demonstrate vasodilatory and hypotensive effects in pharmacological studies. Berbamine and oxyacanthine are calcium channel blockers. Berberine promotes endothelial nitric oxide production. Some clinical studies have reported modest blood pressure reductions as a secondary outcome in berberine trials for metabolic conditions. The hypotensive effect is mild and barberry should be considered adjunctive rather than primary antihypertensive therapy.
[11, 12]Immune System
Gastrointestinal infections and acute infectious diarrhea
Berberine's broad-spectrum antimicrobial activity against GI pathogens (Vibrio cholerae, E. coli, Salmonella, Shigella, Giardia, Entamoeba) is well-documented in vitro and in clinical trials. The antimicrobial action combines with antisecretory effects (inhibition of enterotoxin-induced intestinal fluid secretion) and anti-inflammatory modulation to provide a multi-targeted approach to GI infections. This is one of the most historically validated applications of berberine-containing plants, with a clinical evidence base spanning decades.
[4, 9, 11]Urinary tract infections (supportive)
Traditional use of barberry for urinary complaints, including urinary tract infections, is documented in Eclectic medicine, Unani medicine, and European folk medicine. Berberine is partially excreted renally, providing direct antimicrobial exposure in the urinary tract. In vitro activity against common UTI pathogens (E. coli, Klebsiella) has been documented. However, clinical trial evidence specific to UTI treatment with barberry or berberine is limited. Best used as part of a comprehensive herbal UTI approach.
[5, 11]Skin / Integumentary
Skin infections and inflammatory skin conditions
Barberry has been used both internally and topically for skin conditions including acne, boils, abscesses, and inflammatory dermatoses. The alterative and hepatoprotective actions (improving hepatic detoxification and elimination) combined with direct antimicrobial and anti-inflammatory effects provide the therapeutic rationale. Eclectic physicians recommended barberry for chronic skin diseases associated with hepatic insufficiency. The related species B. aquifolium (Oregon Grape) has stronger clinical evidence for psoriasis specifically (Mahonia aquifolium cream studies), and this evidence is sometimes extrapolated to other berberine-containing Berberis species.
[1, 5]Urinary System
Urinary tract support and mild diuresis
Traditional use in Eclectic and Unani medicine for urinary complaints, including nephrolithiasis (kidney stones), urinary tract infections, and as a mild diuretic. Felter and Lloyd (1898) described barberry as useful for 'renal congestion' and as a 'stimulant to the kidneys.' The evidence base is primarily traditional, with limited modern clinical data specific to urinary applications of B. vulgaris. Berberine's renal excretion provides a rationale for urinary tract antimicrobial effects.
[5, 6]Musculoskeletal System
Arthritis and rheumatic complaints (adjunctive)
Traditional use of barberry as an alterative for arthritic and rheumatic conditions is documented in Eclectic medicine and European folk practice. The anti-inflammatory (NF-kB, COX-2 inhibition) and alterative (hepatic-clearing) actions provide pharmacological rationale. Berberine has demonstrated suppression of inflammatory mediators relevant to arthritis in preclinical studies. Clinical evidence specific to barberry or berberine for arthritis is limited, though the broad anti-inflammatory evidence provides indirect support.
[5, 11]Energetics
Temperature
cold
Moisture
dry
Taste
Tissue States
hot/excitation, damp/stagnation, damp/relaxation
Barberry is one of the classic cold, dry bitter herbs in Western herbal energetics. Its intensely bitter taste and cooling nature make it specific for conditions of excess heat and dampness, particularly in the hepatobiliary and gastrointestinal systems. The pronounced bitter quality is the dominant taste experience from bark preparations and drives the digestive-stimulating and cholagogue effects. The sour taste is contributed by the fruit (malic and citric acids) and, to a lesser degree, by the acidic quality of berberine salts. In terms of tissue states, barberry is best suited for: (1) hot/excitation states -- infections, inflammatory conditions, hepatic inflammation, 'hot' diarrhea and dysentery with fever; (2) damp/stagnation states -- biliary congestion, hepatic stagnation, sluggish digestion with coated tongue and poor appetite, metabolic syndrome with insulin resistance; and (3) damp/relaxation states -- atonic conditions of the GI mucosa with loose stools and poor digestive tone. Barberry is LESS suitable for cold/depressed constitutional types or dry, depleted conditions, where its cooling and drying nature could aggravate the tissue state. In Unani (Graeco-Islamic) medicine, barberry is classified as cold and dry in the second degree. In Ayurveda (applied to the closely related B. aristata), it is considered to balance Pitta and Kapha doshas while potentially aggravating Vata when used excessively. CAVEAT: Herbal energetics are interpretive frameworks within Western herbalism, Unani, and Ayurveda, not standardized across all practitioners.
Traditional Uses
Eclectic American medicine (19th-early 20th century)
- Specific indication for jaundice, hepatic torpor, and bilious conditions
- Cholagogue and bitter tonic for dyspepsia and loss of appetite
- Treatment of chronic diarrhea and dysentery
- Alterative for chronic skin diseases (eczema, psoriasis, acne) attributed to hepatic insufficiency
- Mild laxative for constipation with biliary congestion
- Urinary tract support for 'renal congestion' and painful urination
- External application of decoction for sore throat, mouth ulcers, and conjunctivitis
"Felter and Lloyd (1898) in King's American Dispensatory state: 'Barberry is a tonic and laxative, and is useful in jaundice, chronic diarrhea, and dysentery, and as a general tonic in debilitated states of the system... It is especially adapted to cases exhibiting feebleness of the digestive organs, with hepatic torpor, sallow complexion, and general malassimilation.' They further note: 'The American Eclectics valued berberis as a remedy for jaundice with enlarged or congested liver... it improves appetite, aids digestion, and promotes the secretion and excretion of bile.'"
Unani (Graeco-Islamic) medicine
- Classified as cold and dry in the second degree (Mizaj: Barid wa Yabis daraja-e-duvvum)
- Liver tonic and treatment for hepatobiliary disorders, particularly jaundice (Yaraqan)
- Treatment of fevers, especially bilious fevers
- Diarrhea and dysentery (Ishal and Zaheer)
- External application for eye diseases, particularly conjunctivitis and trachoma
- Fruit used as a refrigerant and thirst-quencher in febrile conditions
- Blood purifier (Musaffi-e-Dam) for skin diseases and boils
"Ibn Sina (Avicenna) in Al-Qanun fi al-Tibb (The Canon of Medicine, ca. 1025 CE) describes barberry (Ambar-baris/Zarishk) as having cold and dry temperament, useful for liver diseases, jaundice, and bilious complaints. The root bark and fruit are both discussed. The fruit is described as beneficial for fevers and thirst, while the root bark is indicated for liver and spleen conditions. Avicenna further notes its utility in strengthening the stomach and resolving hepatic obstructions."
European folk medicine
- Treatment of jaundice, liver complaints, and gallstones
- Fever reduction (fruit and root bark decoctions)
- Treatment of diarrhea and intestinal infections
- Sore throat and mouth sores (gargle with bark decoction)
- External wash for wounds, skin infections, and eye inflammations
- Fruit preserves and syrups as tonic and source of vitamin C
- Dye source: the bright yellow inner bark was used to dye wool, leather, and linen
"Nicholas Culpeper (1653) in The English Physician described barberry: 'The shrub is as well known by every boy that looks upon a hedge, as his father... The inner bark is very yellow, and if broken, makes a beautiful yellow colour. Mars owns the shrub, and presents it to the use of my friends thus: The fruit and the rind of the root are cooling and drying, and effectual against all hot agues, and burning fevers... They are also good for the yellow jaundice, and are effectual against the itch, boils, and eruptions of the skin.'"
Iranian traditional medicine (Persian medicine)
- Root bark for liver diseases, jaundice, and hepatic congestion
- Fruit (zereshk) as a culinary ingredient and food-medicine: added to rice, stews, and syrups
- Fruit syrup (sharbat-e zereshk) for fever, thirst, and as a cooling tonic in summer
- Treatment of high blood pressure and palpitations
- Biliary and gallbladder complaints
- Blood sugar regulation in traditional diabetes management
- External use of bark decoction for gum disease and toothache
"Iran is one of the world's largest producers and consumers of barberry fruit (zereshk), particularly the seedless cultivar 'Bi-dana' from South Khorasan province. The fruit is both an important culinary ingredient (zereshk polo, barberry rice, is a classic Persian dish) and a valued medicine. Iranian traditional medicine texts describe barberry as cooling, liver-strengthening, and blood-purifying. Contemporary Iranian pharmacological research on B. vulgaris is extensive, reflecting the cultural importance of this plant."
Ayurveda (using the closely related Berberis aristata — Daruharidra)
- Daruharidra ('wood turmeric') used for jaundice (Kamala) and liver disorders
- Eye diseases: conjunctivitis, ophthalmia (topical decoction as eye wash — Netra Roga)
- Skin diseases, wounds, and ulcers (Kushtha, Vrana)
- Fever and malarial conditions (Jwara)
- Diarrhea and dysentery (Atisara, Pravahika)
- Diabetes (Prameha) and urinary disorders
- Balances Pitta and Kapha doshas; may aggravate Vata in excess
"While B. vulgaris is not native to the Indian subcontinent, the closely related B. aristata (Daruharidra) is one of the most important herbs in Ayurvedic medicine and shares the berberine-rich chemical profile. The Charaka Samhita and Sushruta Samhita describe Daruharidra for the conditions listed above. The name 'Daruharidra' means 'wood turmeric,' reflecting both the yellow color (like turmeric/haridra) and the woody nature of the plant material. The pharmacological equivalence of Berberis species used in Ayurveda and the European B. vulgaris is well-recognized."
British herbal tradition and the British Herbal Pharmacopoeia
- Cholagogue for gallbladder disease and biliary dysfunction
- Bitter tonic for dyspepsia and anorexia
- Hepatoprotective in chronic hepatic conditions
- Mild laxative for constipation associated with hepatobiliary insufficiency
- Ingredient in bitters formulas for digestive support
"The British Herbal Pharmacopoeia (1983) provides an official monograph for Berberis vulgaris bark, listing its actions as cholagogue, anti-emetic, bitter tonic, and laxative. Specific indications include cholecystitis, gallbladder disease, cholelithiasis, and jaundice. The monograph specifies preparations and dosages, establishing barberry as a recognized medicinal herb in the British herbal tradition."
Modern Research
Comprehensive pharmacological review of Berberis vulgaris
A comprehensive review article covering the pharmacological and therapeutic properties of B. vulgaris, including antimicrobial, anti-inflammatory, hepatoprotective, antioxidant, hypoglycemic, hypolipidemic, and cardiovascular effects. Reviews both traditional uses and modern pharmacological evidence.
Findings: Documented the wide range of pharmacological activities attributable to berberine and the total alkaloid fraction of B. vulgaris. Confirmed antimicrobial activity against Gram-positive and Gram-negative bacteria, fungi, and protozoa. Documented hepatoprotective effects in multiple animal models. Reviewed cardiovascular effects including vasodilation (via endothelium-dependent and calcium channel-mediated mechanisms), negative chronotropic effects, and antiarrhythmic activity of berberine and berbamine. Noted anti-inflammatory activity through NF-kB inhibition, COX-2 suppression, and cytokine modulation. Identified AMPK activation as a central mechanism underlying metabolic (hypoglycemic and hypolipidemic) effects. Concluded that B. vulgaris has a strong pharmacological basis for many of its traditional therapeutic applications.
Limitations: Narrative review; not a systematic review with meta-analysis. Many studies reviewed used purified berberine rather than whole barberry extracts, so direct extrapolation to whole-herb clinical use requires caution. The review highlighted the need for more clinical trials specifically using B. vulgaris preparations.
[11]
Pharmacological review of Berberis species alkaloids
Review of the pharmacological properties of alkaloids from Berberis species, with emphasis on berberine, berbamine, and oxyacanthine. Covers antimicrobial, cardiovascular, anti-inflammatory, and metabolic activities.
Findings: Detailed the structure-activity relationships of isoquinoline alkaloids from Berberis species. Berberine demonstrated antimicrobial activity through DNA intercalation, protein synthesis inhibition, and cell membrane disruption. Berbamine exhibited calcium channel blocking and anti-leukopenic activities. Oxyacanthine demonstrated hypotensive and anti-inflammatory effects. The review documented berberine's inhibition of bacterial efflux pumps, suggesting potential for enhancing antibiotic efficacy against resistant organisms. Cardiovascular effects of the combined alkaloid profile include vasodilation, negative inotropy and chronotropy, and antiarrhythmic activity.
Limitations: Primarily pharmacological review without clinical trial data analysis. Many findings from in vitro and animal studies with uncertain clinical relevance. Structure-activity relationships for complex alkaloid mixtures in whole-plant preparations are difficult to predict from single-compound data.
[12]
Antioxidant and antimicrobial activity of Berberis vulgaris
Investigation of antioxidant capacity and antimicrobial activity of B. vulgaris bark and fruit extracts using multiple assay methods.
Findings: B. vulgaris bark extracts demonstrated strong antioxidant activity in DPPH radical scavenging (IC50 values in the low microgram/mL range), ferric reducing power, and superoxide anion scavenging assays. Bark extracts showed significantly higher antioxidant capacity than fruit extracts, correlated with higher total phenolic and alkaloid content. Antimicrobial testing confirmed activity against S. aureus, E. coli, and C. albicans, with bark extracts more potent than fruit extracts. The study documented that the antioxidant activity of barberry is attributable to both the alkaloid fraction (berberine and related compounds) and the polyphenolic fraction (tannins, phenolic acids).
Limitations: In vitro study only; antioxidant and antimicrobial activity in laboratory assays does not directly predict clinical efficacy. Tested extracts rather than standardized clinical preparations. No dose-response clinical correlation.
[10]
Berberine for type 2 diabetes: meta-analysis of randomized controlled trials
Systematic review and meta-analysis of 14 RCTs (n=1068) evaluating the efficacy and safety of berberine for type 2 diabetes mellitus, alone or as add-on therapy to standard hypoglycemic agents.
Findings: Berberine significantly reduced fasting blood glucose (WMD -0.90 mmol/L, P < 0.00001), HbA1c (WMD -0.72%, P < 0.0001), postprandial blood glucose (WMD -1.27 mmol/L, P < 0.0001), fasting insulin (WMD -1.05 mU/L, P = 0.05), and HOMA-IR (WMD -0.67, P = 0.04) compared to placebo or lifestyle intervention. In head-to-head comparisons with metformin (4 trials), berberine showed comparable glucose-lowering efficacy with no statistically significant differences. Berberine also significantly reduced total cholesterol, LDL-C, and triglycerides as secondary outcomes. Incidence of gastrointestinal adverse events (diarrhea, constipation, flatulence, abdominal pain) was reported but generally mild and transient.
Limitations: All included trials were conducted in Chinese populations, limiting generalizability. Moderate to high heterogeneity across trials. Most trials used purified berberine hydrochloride (typically 500 mg TID), NOT whole barberry extracts -- direct extrapolation to whole-plant preparations requires caution regarding dose equivalence. Short trial durations (8-24 weeks). Risk of publication bias in Chinese-language literature. Quality of some included trials was rated moderate.
[7]
Berberine for dyslipidemia: meta-analysis of randomized controlled trials
Meta-analysis of 27 RCTs (n=2569) evaluating the lipid-lowering effects of berberine in patients with dyslipidemia, conducted alone or in combination with conventional lipid-lowering agents.
Findings: Berberine significantly reduced total cholesterol (WMD -0.61 mmol/L, 95% CI -0.83 to -0.39), LDL-cholesterol (WMD -0.65 mmol/L, 95% CI -0.75 to -0.56), and triglycerides (WMD -0.50 mmol/L, 95% CI -0.69 to -0.31), while modestly increasing HDL-cholesterol (WMD 0.05 mmol/L, 95% CI 0.02 to 0.09). When combined with statins, berberine provided additional lipid-lowering benefit beyond statin monotherapy. The unique mechanism of action (LDL receptor upregulation via mRNA stabilization and PCSK9 inhibition) is complementary to statin-mediated HMG-CoA reductase inhibition, providing a pharmacological rationale for combination use.
Limitations: Again, nearly all trials used purified berberine, not whole barberry. Chinese population bias. Heterogeneous trial designs. Short to moderate treatment durations. Some trials had methodological limitations. Long-term cardiovascular outcome data not available.
[8]
Berberine for secretory diarrhea (cholera)
Randomized, placebo-controlled trial evaluating berberine for acute watery diarrhea in adult patients with culture-positive Vibrio cholerae infection.
Findings: Berberine (400 mg single dose) significantly reduced mean stool volume at 24 hours by 48% compared to placebo in cholera patients. Duration of diarrhea was also reduced. The antisecretory effect of berberine was independent of antimicrobial action, as vibrio clearance rates were similar between groups. Berberine directly inhibits chloride ion secretion mediated by cholera toxin activation of intestinal adenylate cyclase. The study established berberine as an effective antisecretory agent in infectious diarrhea, distinct from its antimicrobial activity.
Limitations: Single-center trial in Bangladesh. Acute setting only. Single-dose protocol. Primarily demonstrated antisecretory mechanism rather than antimicrobial cure. May not generalize to non-cholera diarrheal diseases. Used purified berberine sulfate, not whole barberry.
[9]
Berberine pharmacokinetics and drug interaction potential
Pharmacokinetic studies characterizing berberine absorption, metabolism, and potential for cytochrome P450 and P-glycoprotein interactions.
Findings: Berberine demonstrates low oral bioavailability (< 5% in most pharmacokinetic studies) due to extensive first-pass metabolism by CYP2D6, CYP1A2, and CYP3A4, and active efflux by P-glycoprotein (P-gp/ABCB1) in the intestinal epithelium. Despite low systemic bioavailability, berberine achieves therapeutically relevant concentrations in the GI tract (explaining its effectiveness in GI infections) and liver (first-pass effect concentrates berberine in hepatocytes, explaining hepatic effects). In vitro studies demonstrate that berberine inhibits CYP3A4, CYP2D6, and CYP2C9, and inhibits P-glycoprotein-mediated drug efflux. Clinical drug interaction studies have confirmed increased bioavailability of cyclosporine when co-administered with berberine, attributed to CYP3A4 and P-gp inhibition. These interactions are clinically significant and form the basis for drug interaction warnings.
Limitations: Pharmacokinetic data primarily from animal studies and small human PK studies. In vitro enzyme inhibition may not directly predict clinical interaction magnitude. Dose-dependent PK interactions not fully characterized. Whole barberry preparations would deliver lower berberine doses than purified supplements, potentially reducing but not eliminating interaction risk.
Berberine and gut microbiome modulation
Emerging research on berberine's effects on gut microbiome composition and the role of microbial metabolism in berberine's therapeutic effects, particularly for metabolic diseases.
Findings: Recent studies demonstrate that berberine significantly alters gut microbiome composition, increasing short-chain fatty acid (SCFA)-producing bacteria (Akkermansia, Faecalibacterium, Roseburia) while reducing pathogenic species. The gut microbiome converts berberine to dihydroberberine, which has improved intestinal absorption (5-fold higher) compared to parent berberine, partially explaining the apparent paradox of clinical efficacy despite low oral bioavailability. Berberine-induced microbiome changes correlate with improvements in metabolic parameters (glucose, lipids, inflammation) and may represent a major mechanism of action for metabolic indications. This 'microbiome-mediated bioactivation' model reframes berberine pharmacology from a simple drug absorption paradigm to a more complex host-microbiome interaction.
Limitations: Microbiome research is an emerging field with methodological variability. Causal relationships between specific microbial changes and clinical outcomes are not fully established. Most studies are observational or preclinical. Human microbiome responses are highly individual.
Preparations & Dosage
Decoction
Strength: 1:125 to 1:175 (approximately 2-4 g per 250-500 mL water)
Use dried root bark or stem bark, chopped or coarsely ground. Add 1-2 teaspoons (approximately 2-4 g) of dried bark to 250-350 mL of cold water. Bring to a boil, then reduce heat and simmer gently for 10-15 minutes. Strain and drink. The resulting decoction will be bright yellow and intensely bitter. A second decoction from the same bark material may be prepared by adding fresh water and simmering again for 10 minutes.
1-2 g dried bark per cup, 2-4 g per day total. Drink in 2-3 divided doses before meals for optimal bitter tonic effect.
Two to three times daily, ideally 15-30 minutes before meals
Short to medium-term use (2-8 weeks) for acute conditions. May be used intermittently for chronic conditions with periodic breaks. Not recommended for continuous long-term use without practitioner supervision.
Not recommended for children under 12 due to alkaloid content and lack of pediatric safety data.
Decoction is the traditional preparation method for barberry bark and is appropriate given the woody, dense nature of the bark material. The extended simmering extracts both water-soluble alkaloids (berberine salts are partially water-soluble) and tannins. The intense bitterness is a sign of alkaloid extraction and should not be masked excessively, as the bitter taste itself triggers the digestive cephalic phase response. If the taste is intolerable, small amounts of honey or licorice root can be added. Decoction is preferred over simple infusion for bark preparations due to the need for more vigorous extraction.
Tincture
Strength: 1:5 in 45% ethanol (BHP standard); some practitioners use 1:3 in 60% ethanol for a more concentrated preparation
Use dried root bark or stem bark, finely chopped or coarsely powdered. Standard maceration: 1:5 ratio in 45-60% ethanol. Macerate for 2-4 weeks with daily agitation. Press and filter through muslin or fine filter paper. The tincture will be bright golden-yellow to orange.
1-3 mL (20-60 drops) three times daily before meals. Start at the lower end and increase as tolerated.
Three times daily, ideally 15-30 minutes before meals for digestive indications
2-8 weeks for acute conditions. May be used intermittently for chronic conditions.
Not recommended for children under 12
Tincture is the most common preparation in contemporary Western herbal practice. The hydroalcoholic solvent efficiently extracts both alkaloids (berberine is soluble in alcohol and water) and tannins. Higher alcohol percentages (60%) may extract a broader range of alkaloids. The tincture can be taken in a small amount of water before meals. The bright yellow color is a quality indicator -- a pale or colorless tincture suggests poor extraction or low-quality starting material. Commonly combined with other digestive or hepatic herbs in formula (e.g., with Taraxacum root, Cynara leaf, Gentiana root, or Chelidonium).
Capsule / Powder
Strength: Crude bark powder: 250-500 mg per capsule. Standardized extracts vary by manufacturer; many berberine supplements standardize to 97% berberine HCl purity at 500 mg per capsule.
Dried root bark, finely powdered (ground to pass through a 60-80 mesh sieve), filled into vegetarian or gelatin capsules. Alternatively, a standardized dried extract concentrated for berberine content.
Crude powder: 250-500 mg per capsule, 1-2 capsules 2-3 times daily (total 500-3000 mg crude powder per day). Standardized berberine extract: follow product-specific dosing, typically delivering 500-1500 mg berberine per day in divided doses.
2-3 times daily with meals for metabolic indications; before meals for digestive indications
Short to medium-term clinical courses (4-12 weeks). Extended use under practitioner supervision.
Not recommended for children under 12
Capsules bypass the bitter taste, which is convenient but eliminates the cephalic phase digestive stimulation that is an important component of barberry's bitter tonic action. For digestive indications specifically, tincture or decoction (where the bitter taste is experienced) may be preferable. For metabolic indications (blood sugar, lipids), capsules of standardized berberine extract deliver more consistent dosing. IMPORTANT: Many commercially available 'berberine' capsules contain purified berberine hydrochloride derived from various plant sources (often Coptis chinensis or Berberis aristata), not B. vulgaris specifically. Whole barberry root bark capsules provide the full alkaloid spectrum (berberine + berbamine + oxyacanthine + palmatine etc.) which may have a different therapeutic profile than isolated berberine.
Standardized Extract
Strength: Purified berberine HCl: 500 mg per capsule, 97% purity. Whole-bark standardized extracts: variable, typically 4:1 to 10:1 concentration ratio.
Commercially prepared standardized extracts of B. vulgaris bark or purified berberine supplements. Products are typically standardized to minimum berberine content (commonly 85-97% berberine hydrochloride for purified supplements, or specified alkaloid percentages for whole-bark extracts).
Berberine HCl: 500 mg 2-3 times daily (total 1000-1500 mg/day) is the dosage most commonly used in clinical trials for metabolic indications. Whole barberry standardized extract: dose varies by extraction ratio; follow manufacturer guidelines.
Two to three times daily with meals (taking with food reduces GI side effects)
Clinical trials typically 8-24 weeks. Extended use under medical supervision for metabolic conditions.
Not established for standardized extract form
Standardized extracts and purified berberine supplements are the forms used in the majority of published clinical trials, particularly for metabolic indications (diabetes, dyslipidemia). The distinction between purified berberine and whole barberry extract is clinically important: purified berberine delivers a single active compound at higher doses, while whole-herb preparations deliver a spectrum of synergistic alkaloids at lower individual berberine doses. Some practitioners prefer whole-plant preparations based on the principle of synergy, while others prefer the dosing precision and clinical evidence base of standardized berberine. Gastrointestinal side effects (mainly diarrhea, constipation, or abdominal discomfort) are the most common adverse effects at clinical trial doses, usually mild and transient.
Syrup
Strength: Variable depending on concentration. Fruit syrup: approximately 1 part fruit to 1 part water to 0.6-0.8 parts sweetener.
Barberry fruit syrup (traditional Persian preparation): Wash 500 g fresh barberries and simmer in 500 mL water for 15-20 minutes until soft. Strain through cheesecloth, pressing to extract all juice. Return juice to heat, add 300-400 g sugar or honey, and simmer gently until syrup consistency is reached (approximately 20 minutes). Bottle hot in sterilized glass jars. For a medicinal bark syrup: prepare a concentrated bark decoction (30 g bark simmered in 500 mL water for 30 minutes, reduced to 250 mL), strain, and add equal volume of honey.
Fruit syrup: 1-2 tablespoons (15-30 mL) 2-3 times daily, diluted in water as a refreshing drink. Bark syrup: 1-2 teaspoons (5-10 mL) 2-3 times daily.
2-3 times daily
Consume within 2-3 months if refrigerated. Fruit syrup suitable for long-term use; bark syrup for intermittent courses.
Fruit syrup: 1-2 teaspoons for children over 5 (low alkaloid content in fruit). Bark syrup: not recommended for children under 12.
Barberry fruit syrup is a traditional Iranian and Eastern European preparation with a long history of household use. The fruit-based syrup is essentially a food-medicine with minimal alkaloid content, pleasant tart flavor (comparable to cranberry), and cooling, refreshing properties. It is used as a general tonic, febrifuge, and appetizer. The bark-based medicinal syrup is less traditional but provides a palatable way to administer the bitter bark preparation, particularly for patients who cannot tolerate the intense bitterness of decoction or tincture.
Safety & Interactions
Class 2a
Not to be used during pregnancy (AHPA Botanical Safety Handbook)
Contraindications
Berberine has demonstrated uterotonic (uterine-stimulating) activity in animal studies and isolated uterine tissue preparations, increasing both the frequency and amplitude of uterine contractions. Berberine also crosses the placental barrier and has been shown to displace bilirubin from albumin binding sites, which could theoretically increase the risk of neonatal jaundice (kernicterus) if used late in pregnancy. The American Herbal Products Association (AHPA) Botanical Safety Handbook classifies B. vulgaris as Class 2a (not to be used during pregnancy). Multiple authoritative references (German Commission E, WHO, AHPA) concur that barberry and berberine-containing preparations should be avoided during pregnancy.
Although rare, allergic reactions to barberry or berberine have been reported. Individuals with confirmed allergy to any Berberis species should not use barberry preparations.
Berberine displaces bilirubin from albumin binding sites in vitro. While this is primarily a concern for direct neonatal exposure, breastfeeding mothers should avoid berberine-containing preparations as a precaution during the neonatal period when the infant's bilirubin metabolism is immature.
Due to barberry's potent cholagogue action (stimulation of bile flow), it should not be used when there is mechanical obstruction of the bile duct (e.g., large gallstones lodged in the common bile duct, biliary tumors). Stimulating bile flow against an obstruction could theoretically exacerbate symptoms and increase the risk of biliary colic or pancreatitis. This contraindication applies to all cholagogue herbs and is not unique to barberry.
Drug Interactions
| Drug / Class | Severity | Mechanism |
|---|---|---|
| Cyclosporine (Immunosuppressants) | major | Berberine inhibits CYP3A4 and P-glycoprotein (P-gp), both of which are major determinants of cyclosporine metabolism and transport. Co-administration significantly increases cyclosporine blood levels. Wu et al. (2005) demonstrated a clinically significant increase in cyclosporine AUC and Cmax in renal transplant patients taking berberine concurrently. |
| CYP3A4 substrates (e.g., statins [atorvastatin, simvastatin], calcium channel blockers, benzodiazepines, HIV protease inhibitors) (Various (CYP3A4-metabolized drugs)) | moderate | Berberine inhibits CYP3A4 in vitro and in vivo. Co-administration with CYP3A4 substrates may decrease their metabolism, leading to increased blood levels and potential toxicity. The magnitude of inhibition may vary with berberine dose and individual CYP3A4 activity. |
| P-glycoprotein substrates (e.g., digoxin, fexofenadine, colchicine, dabigatran) (Various (P-gp substrates)) | moderate | Berberine inhibits P-glycoprotein-mediated efflux transport. Co-administration with P-gp substrates may increase their intestinal absorption and decrease their renal/biliary clearance, leading to elevated blood levels. |
| Metformin and other oral hypoglycemic agents (sulfonylureas, thiazolidinediones) (Hypoglycemic agents) | moderate | Additive blood glucose-lowering effect. Berberine lowers blood glucose through AMPK activation, improved insulin sensitivity, and reduced hepatic glucose output -- mechanisms that are additive or synergistic with those of metformin and other hypoglycemic agents. |
| Antihypertensive medications (Antihypertensives) | minor | Additive blood pressure-lowering effect. Berberine, berbamine, and oxyacanthine demonstrate vasodilatory and hypotensive activity through endothelial NO production, calcium channel blockade, and other mechanisms. |
| Anticoagulants and antiplatelet agents (warfarin, heparin, aspirin, clopidogrel) (Anticoagulants/Antiplatelets) | theoretical | Berberine has demonstrated antiplatelet activity in vitro (inhibition of thromboxane synthesis and platelet aggregation). Additionally, CYP-mediated drug interaction may affect warfarin metabolism. Theoretical risk of additive anticoagulant/antiplatelet effect. |
| Sedatives and CNS depressants (benzodiazepines, barbiturates) (Sedatives/CNS depressants) | minor | Berberine has demonstrated mild sedative and CNS depressant activity in animal studies. Additionally, CYP3A4 inhibition by berberine may increase levels of CYP3A4-metabolized benzodiazepines (alprazolam, midazolam, triazolam). |
| Antibiotics (tetracyclines, macrolides, fluoroquinolones) (Antibiotics) | minor | Berberine may have synergistic antimicrobial effects with certain antibiotics, particularly through inhibition of bacterial efflux pumps (NorA in S. aureus). This is potentially beneficial (enhancing antibiotic efficacy) rather than harmful. |
Pregnancy & Lactation
Pregnancy
unsafe
Lactation
possibly unsafe
PREGNANCY: Barberry and all berberine-containing preparations are contraindicated in pregnancy. Berberine has demonstrated uterotonic activity (stimulation of uterine smooth muscle contractions) in animal studies and in vitro human uterine tissue studies. Berberine crosses the placenta and has the potential to displace bilirubin from albumin binding sites in the fetus/neonate, theoretically increasing the risk of kernicterus. The AHPA Botanical Safety Handbook, German Commission E, and WHO Traditional Medicine guidelines all recommend avoiding berberine-containing plants during pregnancy. This is classified as AHPA Class 2a (not to be used during pregnancy). LACTATION: Insufficient data on excretion of berberine and related alkaloids into breast milk. Given the theoretical risk of neonatal bilirubin displacement and the pharmacological activity of berberine, avoidance during breastfeeding is prudent, especially during the neonatal period (first 28 days). If use is considered in later lactation, it should be under qualified practitioner supervision.
Adverse Effects
References
Monograph Sources
- [1] Hoffmann D. Medical Herbalism: The Science and Practice of Herbal Medicine. Rochester, VT: Healing Arts Press (2003) . ISBN: 978-0892817498
- [2] British Herbal Medicine Association. British Herbal Pharmacopoeia: Berberis vulgaris (Barberry bark). Bournemouth: BHMA (1983)
- [3] Gardner Z, McGuffin M (editors). American Herbal Products Association's Botanical Safety Handbook, 2nd edition: Berberis vulgaris. Boca Raton, FL: CRC Press (2013) . ISBN: 978-1466516946
- [4] World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 4: Cortex Berberidis. Geneva: World Health Organization (2009)
- [5] Felter HW, Lloyd JU. King's American Dispensatory: Berberis. Cincinnati: Ohio Valley Company (1898)
- [6] Ibn Sina (Avicenna). Al-Qanun fi al-Tibb (The Canon of Medicine). Original text ca. 1025 CE; multiple modern translations (1025)
Clinical Studies
- [7] Dong H, Wang N, Zhao L, Lu F. Berberine in the treatment of type 2 diabetes mellitus: a systemic review and meta-analysis. Evid Based Complement Alternat Med (2012) ; 2012 : 591654 . DOI: 10.1155/2012/591654 . PMID: 23118793
- [8] Lan J, Zhao Y, Dong F, Yan Z, Zheng W, Fan J, Sun G. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. J Ethnopharmacol (2015) ; 161 : 69-81 . DOI: 10.1016/j.jep.2014.09.049 . PMID: 25498346
- [9] Rabbani GH, Butler T, Knight J, Sanyal SC, Alam K. Randomized controlled trial of berberine sulfate therapy for diarrhea due to enterotoxigenic Escherichia coli and Vibrio cholerae. J Infect Dis (1987) ; 155 : 979-984 . DOI: 10.1093/infdis/155.5.979 . PMID: 3549923
- [10] Zovko Koncic M, Kremer D, Karlovic K, Kosalec I. Evaluation of antioxidant activities and phenolic content of Berberis vulgaris L. and Berberis croatica Horvat. Food Chem Toxicol (2010) ; 48 : 2176-2180 . DOI: 10.1016/j.fct.2010.05.025 . PMID: 20488220
Traditional Texts
- [11] Imanshahidi M, Hosseinzadeh H. Pharmacological and therapeutic effects of Berberis vulgaris and its active constituent, berberine. Phytother Res (2008) ; 22 : 999-1012 . DOI: 10.1002/ptr.2399 . PMID: 18618524
- [12] Arayne MS, Sultana N, Bahadur SS. The berberis story: Berberis vulgaris in therapeutics. Pak J Pharm Sci (2007) ; 20 : 83-92 . PMID: 17337435
Pharmacopeias & Reviews
- [13] German Federal Institute for Drugs and Medical Devices (BfArM). Commission E Monograph: Berberis vulgaris (Barberry). Bundesanzeiger (Federal Gazette), Germany (1990)
- [14] European Directorate for the Quality of Medicines (EDQM). European Pharmacopoeia, 10th edition. Strasbourg: Council of Europe (2020)
Last updated: 2026-03-02 | Status: review
Unlock the Full Materia Medica
This monograph is part of our complete evidence-based herbal reference. Enter your email to get free, unlimited access to all of our monographs.
No spam, ever. Unsubscribe anytime.
You're In!
You now have full access to all of our herbal monographs.